2. American-Psychiatric-Association. Diagnostic and Statistical Manual of Mental Disorder. 5th Ed. Arlington, VA: American Psychiatric Publishing; 2013.
3. Nelson B, Yuen HP, Wood SJ, Lin A, Spiliotacopoulos D, Bruxner A, et al. Long-term follow-up of a group at ultra high risk (“prodromal”) for psychosis: the PACE 400 study. JAMA Psychiatry 2013;70:793-802.
5. Addington J, Stowkowy J, Weiser M. Screening tools for clinical high risk for psychosis. Early Interv Psychiatry 2015;9:345-356.
6. Chung YC, Kang NI, Im YJ, Kim SW, Cho IH, Lee YM, et al. Validation of the Korean version of the Eppendorf Schizophrenia Inventory as a screening measure to detect adolescents at ultra-high risk for psychosis. Early Interv Psychiatry 2013;7:71-79.
11. Mass R, Girndt K, Matouschek AK, Peter PM, Plitzko N, Andresen B, et al. Introducing the Eppendorf Schizophrenia Inventory (ESI) as a psychometric method for schizotypy research. Pers Individ Dif 2007;42:525-534.
12. Capra C, Kavanagh DJ, Hides L, Scott J. Brief screening for psychosislike experiences. Schizophr Res 2013;149:104-107.
14. Stefanis NC, Hanssen M, Smirnis NK, Avramopoulos DA, Evdokimidis IK, Stefanis CN, et al. Evidence that three dimensions of psychosis have a distribution in the general population. Psychol Med 2002;32:347-358.
15. Bukenaite A, Stochl J, Mossaheb N, Schäfer MR, Klier CM, Becker J, et al. Usefulness of the CAPE-P15 for detecting people at ultra-high risk for psychosis: Psychometric properties and cut-off values. Schizophr Res 2017;189:69-74.
16. Núñez D, Arias V, Vogel E, Gómez L. Internal structure of the Community Assessment of Psychic Experiences- Positive (CAPE-P15) scale: evidence for a general factor. Schizophr Res 2015;165:236-242.
17. Perez J, Russo DA, Stochl J, Clarke J, Martin Z, Jassi C. Common mental disorder including psychotic experiences: trailblazing a new recovery pathway within the improving access to psychological therapies programme in England. Early Interv Psychiatry 2018;12:497-504.
18. Chung YC, Jung HY, Kim SW, Lee SH, Shin SE, Shin YM, et al. What factors are related to delayed treatment in individuals at high risk for psychosis? Early Interv Psychiatry 2010;4:124-131.
19. Han C, Jo SA, Kwak JH, Pae CU, Steffens D, Jo I, et al. Validation of the Patient Health Questionnaire-9 Korean version in the elderly population: the Ansan Geriatric study. Compr Psychiatry 2008;49:218-223.
20. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient Health Questionnaire. JAMA 1999;282:1737-1744.
21. O’Toole BI. Screening for low prevalence disorders. Aust N Z J Psychiatry 2000;34(Suppl):S39-S46.
22. Owoso A, Ndetei DM, Mbwayo AW, Mutiso VN, Khasakhala LI, Mamah D. Validation of a modified version of the PRIME screen for psychosis-risk symptoms in a non-clinical Kenyan youth sample. Compr Psychiatry 2014;55:380-387.
24. Post SG. Preventing schizophrenia and Alzheimer disease: comparative ethics. Schizophr Res 2001;51:103-108.
25. Kim SW, Polari A, Melville F, Moller B, Kim JM, Amminger P, et al. Are current labeling terms suitable for people who are at risk of psychosis? Schizophr Res 2017;188:172-177.
26. Moritz S, Göritz AS, McLean B, Westermann S, Brodbeck J. Do depressive symptoms predict paranoia or vice versa? J Behav Ther Exp Psychiatry 2017;56:113-121.
27. Kline ER, Seidman LJ, Cornblatt BA, Woodberry KA, Bryant C, Bearden CE, et al. Depression and clinical high-risk states: Baseline presentation of depressed vs. non-depressed participants in the NAPLS-2 cohort. Schizophr Res 2018;192:357-363.
29. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 2004;185:291-297.